Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28059764 | 0.78 | L3MBTL1 (0.38) | L3MBTL1ATMLMNACYP2B6CHRM3 | |
| SCHEMBL11638601 | 0.78 | CYP2B6 (0.50) | L3MBTL1ATMLMNACYP2B6CHRM3 | |
| SCHEMBL6552278 | 0.74 | CYP2B6 (0.62) | L3MBTL1ATMLMNACYP2B6CHRM3 | |
| SCHEMBL27836974 | 0.73 | CHRM3 (0.47) | CHRM3CHRM2 | |
| SCHEMBL10587965 | 0.72 | CARM1 (0.50) | LMNACHRM3CHRM2 | |
| SCHEMBL16226840 | 0.71 | CYP2B6 (0.41) | L3MBTL1ATMLMNACYP2B6CHRM3 | |
| SCHEMBL5139721 | 0.70 | OPRD1 (0.49) | LMNACYP2B6CHRM3CHRM2 | |
| SCHEMBL11541847 | 0.70 | SMN1; SMN2 (0.54) | LMNACYP2B6 | |
| SCHEMBL12099195 | 0.68 | CYP2B6 (0.53) | L3MBTL1ATMLMNACYP2B6CHRM3 | |
| SCHEMBL12488968 | 0.68 | CYP2B6 (0.53) | L3MBTL1ATMLMNACYP2B6CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20010009921-A1 | Less tendency to cause drug dependency, analgesic, anesthetic, anti-inflammatory or neuroprotective agent; subtype of opoid receptor | ITO FUMITAKA (JP) | 2001-07-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010009921-A1 | Less tendency to cause drug dependency, analgesic, anesthetic, anti-inflammatory or neuroprotective agent; subtype of opoid receptor | OPRL1, OPRD1, OPRK1 | L3MBTL1 324/4885ATM 4715/4885LMNA 2522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.